Introduction {#s1}
============

Thyroid dysfunction is common around the world. In endocrine practice, thyroid abnormalities take around 30% to 40% of the cases ([@B12]). About 5% to 20% of American adult population has thyroid abnormalities ([@B2]) with 1% to 2% in UK adults ([@B45]) 17% to 35% in Brazilian women ([@B42]) 10% in Japanese adults ([@B17]) and 1 in 5788 live births occurring in Taiwan ([@B44]).

Postoperative hypothyroidism is a major complication after thyroid disorders surgeries, appeared in 32.8% of the cases in the series reported by [@B4]. Transient hypothyroidism incidence has been estimated to range from 6.9% to 46% ([@B9]; [@B32]; [@B20]) and permanent hypothyroidism from 0.4% to 33% ([@B39]; [@B1]; [@B47]; [@B9]) nevertheless, it depends on patients follow-up interval and their investigators in how they define hypothyroidism ([@B26]). Hypothyroidism constitutes of several complications such as basal calcification ([@B27]; [@B31]), formation of cataract ([@B15]) electrocardiographic abnormalities ([@B36]) and tetany ([@B30]; [@B5]). Several studies reported that the transient and permanent postoperative hypothyroidism are associated with Graves' disease ([@B46]; [@B10]; [@B33]), thyrotoxicosis ([@B28]) recurrent goiter ([@B47]; [@B40]) and thyroid cancer ([@B25]). Surgical techniques like devascularization or parathyroid glands inadvertent resection are associated with transient and permanent postoperative hypothyroidism ([@B8]; [@B28]). The incidence of hypothyroidism related to different surgical procedures could be accomplished by estimating the risk of different surgical procedures. Despite of whether or not we know the behavior of patients after surgery their metabolism is still unpredictable.

Limited information exists about the relationship between different surgical procedures and risk to develop postoperative transient or permanent hypothyroidism which, for the most part is still unclear. Therefore, we aim to investigate different surgical procedures for thyroid disorders associated with transient or permanent hypothyroidism in the Taiwanese population.

Materials and Methods {#s2}
=====================

Data Source {#s2_1}
-----------

In this study, we used reimbursement data from the Bureau National Health Insurance (BNHI) system in Taiwan which was implemented on March, 1995 and has registered all the medical claims since 1996. More than 99% of Taiwan's citizens are enrolled in the NHI, which offers mandatory and comprehensive medical care coverage to all Taiwanese residents ([@B14]). For research and administrative use, the National Research Institute established a randomly selected claim database which represents the whole population, and provides all information of medical services received by each individual yearly, from 1996 to 2012 ([@B19]). We randomly selected two million samples from Taiwan's NHI beneficiary claim data during the years 1998 to 2011.

Study Population {#s2_2}
----------------

For our observational retrospective cohort study, we identified subjects from January 1, 1998 to December 31, 2010 who were hospitalized with surgeries for thyroid diseases \[Taiwan National Health Insurance (NHI) codes 82001C, 82002C, 82004B, 82008B, 82015B, 82016B), and used the date of surgical procedures as the index date (see [**Table S1**](#SM1){ref-type="supplementary-material"} in Appendix). Moreover, subjects diagnosed with hypoparathyroidism and hypothyroidism before any surgical procedures, were excluded in this study. Initially, all eligible subjects were followed-up until a diagnosis of hypothyroidism \[International Classification of Disease, Clinical Modification, Ninth Revision \[ICD-9-CM) codes 244.0\] or until the time subjects were censored for failure to follow-up, or termination of insurance, or a time beyond December 31, 2011 (see [**Table S1**](#SM1){ref-type="supplementary-material"} in Appendix).

Covariate Assessment {#s2_3}
--------------------

The potential confounders were included in the study. The confounding factors influencing the risk of cancers such as age, gender, location (branch), and socio-economic status (SES) (based on the total amounts of payment to Taiwan's National Health Insurance) were all included in this study. We also identified comorbidities that may be associated with mortality based on diagnostic codes from outpatient datasets prior to the outcome of interest. All diseases were included in the Charlson Comorbidity Index (CCI) and analyzed, except for human immunodeficiency virus (HIV) ([@B3]).

Data Analysis {#s2_4}
-------------

One-way analysis of variance and independent t-test were used to compare each variable among groups undergoing surgery. A p-value of less than 0.05 was considered to be significant. Cumulative incidence curves were estimated by means of the method of Fine and Gray ([@B11]) were compared with the use of a log-rank test. Cox regression models with the duration (days) as the time scale were used to calculate hazard ratio (HR). The multivariable Cox model was adjusted for these confounders listed in [**Table 1**](#T1){ref-type="table"}. We used the SPSS 20 software to perform data analysis and the results calculations were expressed as the estimated numbers together with 95% confidence intervals (CIs).

###### 

Characteristic of hypothyroidism patients for each surgical procedures.

                                         Subtotal        Total           One-side total and another- side subtotal   Radical with unilateral neck   p-value                       
  -------------------------------------- --------------- --------------- ------------------------------------------- ------------------------------ -------------- -------------- ---------
  **N**                                  1475            3037            2324                                        537                            1216           306            --
  **Gender, N (%)**                                                                                                                                                               \<0.001
  **Female**                             1192 (80.81)    2572 (84.69)    1857 (79.91)                                441 (82.12)                    981 (80.67)    240 (78.43)    
  **Male**                               283 (19.19)     465 (15.31)     467 (20.09)                                 96 (17.88)                     235 (19.33)    66 (21.57)     
  **Age**                                                                                                                                                                         \<0.001
  **Mean (SD)**                          45.25 (13.87)   41.44 (14.17)   46.35 (14.04)                               49.25 (13.49)                  45.52 (14.4)   46.54 (14.3)   
  **Comorbid conditions, N (%)**                                                                                                                                                  
  **Myocardial infarction**              11 (0.75)       18 (0.59)       24 (1.03)                                   4 (0.74)                       5 (0.41)       3 (0.98)       0.337
  **Congestive heart failure**           134 (9.08)      196 (6.45)      224 (9.64)                                  47 (8.75)                      103 (8.47)     31 (10.13)     0.001
  **Peripheral vascular disease**        56 (3.8)        98 (3.23)       106 (4.56)                                  34 (6.33)                      65 (5.35)      15 (4.9)       0.002
  **Cerebrovascular disease**            120 (8.14)      188 (6.19)      217 (9.34)                                  70 (13.04)                     130 (10.69)    31 (10.13)     \<0.001
  **Dementia**                           7 (0.47)        13 (0.43)       15 (0.65)                                   5 (0.93)                       14 (1.15)      4 (1.31)       0.064
  **COPD**                               471 (31.93)     956 (31.48)     806 (34.68)                                 216 (40.22)                    481 (39.56)    120 (39.22)    \<0.001
  **Rheumatic disease**                  57 (3.86)       119 (3.92)      181 (7.79)                                  56 (10.43)                     102 (8.39)     28 (9.15)      \<0.001
  **Peptic ulcer disease**               492 (33.36)     1042 (34.31)    897 (38.6)                                  251 (46.74)                    540 (44.41)    132 (43.14)    \<0.001
  **Mild liver disease**                 383 (25.97)     879 (28.94)     679 (29.22)                                 214 (39.85)                    425 (34.95)    113 (36.93)    \<0.001
  **Diabetes**                           172 (11.66)     326 (10.73)     354 (15.23)                                 120 (22.35)                    211 (17.35)    54 (17.65)     \<0.001
  **Hemiplegia or paraplegia**           22 (1.49)       52 (1.71)       49 (2.11)                                   21 (3.91)                      33 (2.71)      5 (1.63)       0.006
  **Renal disease**                      141 (9.56)      218 (7.18)      239 (10.28)                                 68 (12.66)                     115 (9.46)     30 (9.8)       \<0.001
  **Cancer**                             159 (10.78)     192 (6.32)      608 (26.16)                                 297 (55.31)                    137 (11.27)    279 (91.18)    \<0.001
  **Moderate or severe liver disease**   0 (0)           2 (0.07)        5 (0.22)                                    3 (0.56)                       1 (0.08)       0 (0)          0.023
  **Charlson Comorbidities Index**                                                                                                                                                
  **Mean (SD)**                          3.09 (2.93)     2.63 (2.62)     3.79 (3.22)                                 5.28 (3.41)                    3.63 (3.22)    5.53 (3.34)    
  **Location, N (%)**                                                                                                                                                             
  **Taipei**                             438 (29.69)     786 (25.88)     758 (32.62)                                 191 (35.57)                    322 (26.48)    115 (37.58)    
  **Northern**                           138 (9.36)      334 (11)        330 (14.2)                                  52 (9.68)                      123 (10.12)    24 (7.84)      
  **Central**                            238 (16.14)     1009 (33.22)    545 (23.45)                                 121 (22.53)                    281 (23.11)    45 (14.71)     
  **Southern**                           257 (17.42)     477 (15.71)     310 (13.34)                                 60 (11.17)                     173 (14.23)    59 (19.28)     
  **Pingtung**                           367 (24.88)     377 (12.41)     327 (14.07)                                 105 (19.55)                    287 (23.6)     51 (16.67)     
  **Eastern**                            37 (2.51)       54 (1.78)       54 (2.32)                                   8 (1.49)                       30 (2.47)      12 (3.92)      
  **SES, N (%)**                                                                                                                                                                  \<0.001
  **INS_AMT\< = 20,000**                 686 (46.51)     1506 (49.59)    1044 (44.92)                                220 (40.97)                    563 (46.3)     129 (42.16)    
  **20,000 \< INS_AMT\< = 40,000**       610 (41.36)     1231 (40.53)    890 (38.3)                                  217 (40.41)                    491 (40.38)    130 (42.48)    
  **INS_AMT \> 40,000**                  179 (12.14)     300 (9.88)      390 (16.78)                                 100 (18.62)                    162 (13.32)    47 (15.36)     

Ethical Approval {#s2_5}
----------------

This type of study did not require the Institutional Review Board approval according to the policies of the National Health Research Institutes which provides large computerized de-identified data. <http://nhird.nhri.org.tw/en/>. This study contained unidentifiable living individual medical information, that the informed consent is not needed.

Results {#s3}
=======

In this study, we included 8,895 patients who underwent thyroid diseases surgeries. The mean age of patients who undergoing unilateral-subtotal and bilateral-subtotal surgery were 45.25 and 41.25 years respectively. All the demographic characteristics, confounding comorbidities and other factors which could influence the outcomes of subjects are presented in [**Table 1**](#T1){ref-type="table"}. In our study analysis, we classified patients into six different thyroid disorder surgery groups and observed a maximum numbers of patients, where the bilateral-subtotal procedure group was compared to other groups. It is noticeable that among all surgery groups, female patients dominate all groups, ranging from 85% to 87%. We also observed the statistically significant difference in comorbid diseases, regional, and socioeconomic status (P \< 0.001) among different surgical procedures groups.

We analyzed the cumulative incidence for hypothyroidism after adjusting confounding variables among different surgical procedures groups shown in [**Figure 1**](#f1){ref-type="fig"}. It can be seen from the data in [**Figure 1**](#f1){ref-type="fig"} that the bilateral total group revealed 45% cumulative incidence of postoperative hypothyroidism during the 12 years study period. There was no significant difference observed between the bilateral-subtotal (18%) and radical with unilateral neck (17.5%) surgery procedure group. Interestingly the unilateral-subtotal group presented the lowest rate of incidence (10%) among other surgical procedures groups for thyroid disorders.

![Cumulative incidences of hypothyroidism (ICD-9-CM code 244.0) from different surgical procedures.](fphar-10-01378-g001){#f1}

[**Table 2**](#T2){ref-type="table"} presents incidence of developing hypothyroidism in all six surgical procedures groups. The significantly higher risk for developing hypothyroidism was observed in bilateral-total group (HR, 4.27; 95% CI, 3.32--5.50), for one-side total and another-side-subtotal (HR, 3.16; 95% CI, 2.59--3.86), and for bilateral-subtotal (HR, 1.65; 95% CI, 1.37--1.98) shown in [**Table 2**](#T2){ref-type="table"}. However, we did not observe any statistically significant association for unilateral-total (HR, 1.17; 95% CI, 0.95--1.44) with postoperative hypothyroidism. In this study, we also investigated the time interval trends associated with weeks, months and years for postoperative hypothyroidism. We found that among a total of 350 subjects after surgery for a period of 1--4 weeks, 340 developed hypoparathyroidism and which subsided within 8 weeks then patients were stable within 12 weeks ([**Figure 2A**](#f2){ref-type="fig"}). Similar trends were observed for periods of 2--12 months while we followed 480 subjects post thyroid disorder surgery, in which symptoms subsided usually within the second month after surgery ([**Figure 2B**](#f2){ref-type="fig"}). For longer periods (1--12 years), 1000 cases of post thyroid surgery became stable within the first year of surgery and no longer had symptoms by the ending of our study's observation period. The rates of postoperative hypothyroidism were observed as significantly associated with increased occurrences just after surgical procedure but subsided shortly after, indicating a transient postoperative hypothyroidism as shown in [**Figures 2A--C**](#f2){ref-type="fig"}. [**Table 3**](#T3){ref-type="table"} shows the relation of thyroid disorders and the surgical procedures which surgeon selected to perform.

###### 

Hypothyroidism risk after adjusting for surgical procedures.

  Operation procedures                       No.    Hypothyroidism No.   HR (95% CI)\*        P-Value
  ------------------------------------------ ------ -------------------- -------------------- ---------
  Unilateral Subtotal                        1475   153                  148                  
  Bilateral Subtotal                         3037   484                  1.65 (1.37 - 1.98)   \<0.001
  Unilateral Total                           2324   219                  1.17 (0.95 - 1.44)   0.145
  Bilateral Total                            537    126                  4.27 (3.32 - 5.50)   \<0.001
  One-side total and another-side subtotal   1216   289                  3.16 (2.59 - 3.86)   \<0.001
  Radical with unilateral neck               306    31                   1.70 (1.13 - 2.57)   0.011

\*Adjusted for variables as in **Table 1**.

![Postoperative hypothyroidism trends in patients for periods of weeks, months and years. **(A)** presents the incidence of hypothyroidism by week in first 12weeks. **(B)** presents the incidence of hypothyroidism by year. **(C)** presents the incidence of hypothyroidism by month.](fphar-10-01378-g002){#f2}

###### 

The relation of thyroid disorders and the surgical procedures which surgeon selected to perform (Hypothyroidism).

  Surgical Procedure/Thyroid disorders (ICD-9 code)                 Unilateral Subtotal N = 1475   Bilateral Subtotal N = 3037   Unilateral Total N = 2324   Bilateral -Total N = 537   One-side total and another- side subtotal N = 1216   Radical with unilateral neck N = 306   Total
  ----------------------------------------------------------------- ------------------------------ ----------------------------- --------------------------- -------------------------- ---------------------------------------------------- -------------------------------------- -------
  193 (Malignant neoplasm)                                          63 (4.06%)                     75 (2.33%)                    419 (17.38%)                265 (45.06%)               57 (4.55%)                                           275 (88.14%)                           1154
  240 (Simple and unspecified goiter)                               1 (0.06%)                      0                             0                           0                          0                                                    0                                      1
  240.0 (Goiter, specified as simple)                               4 (0.26%)                      4 (0.124%)                    4 (0.16%)                   0                          0                                                    0                                      12
  240.9 (Goiter, unspecified)                                       74 (4.18%)                     82 (2.54%)                    93 (3.85%)                  8 (1.36%)                  53 (4.23%)                                           1 (0.32%)                              311
  241 (Nontoxic nodular goiter)                                     4 (0.26%)                      3 (0.09%)                     0                           0                          0                                                    0                                      7
  241.0 (Nontoxic uninodular goiter)                                137 (8.91%)                    44 (1.36%)                    225 (9.33%)                 3 (0.51%)                  31 (2.47%)                                           11 (3.52%)                             451
  241.1 (Nontoxic multinodular goiter)                              133 (8.65)                     1048 (32.56%)                 246 (10.20%)                141 (23.97%)               340 (27.15%)                                         2 (0.64%)                              1910
  241.9 (Unspecified nontoxic nodular goiter)                       654 (42.57%)                   504 (15.66%)                  867 (35.97%)                53 (9.01%)                 278 (22.20%)                                         4 (1.28%)                              2360
  242 (Thyrotoxicosis with or without goiter)                       0                              5 (0.15%)                     0                           0                          0                                                    0                                      5
  242.0 (Toxic diffuse goiter)                                      0                              11 (0.34%)                    1 (0.041%)                  0                          0                                                    0                                      12
  242.1 (Toxic uninodular goiter)                                   0                              0                             0                           0                          0                                                    0                                      0
  242.2 (Toxic multinodular goiter)                                 0                              0                             0                           0                          0                                                    0                                      0
  242.3 (Toxic nodular goiter unspecified type)                     1 (0.06%)                      0                             0                           0                          0                                                    0                                      1
  242.4                                                             0                              0                             0                           0                          0                                                    0                                      0
  242.8 (Thyrotoxicosis of other specified origin)                  0                              0                             0                           0                          0                                                    0                                      0
  242.9 (Thyrotoxicosis without mention of goiter or other cause)   0                              1 (0.03%)                     0                           0                          0                                                    0                                      1
  Other diseases                                                    404 (27.39%)                   1260 (41.49%)                 469 (20.18%)                67 (12.48%)                457 (37.58%)                                         13 (4.25%)                             2670

Discussion {#s4}
==========

We investigated postoperative hypothyroidism's association with thyroid disorder surgeries in the Taiwanese population. The patients with thyroid disorders undergoing six different surgical procedures allowed us to understand the incidence of postsurgical hypothyroidism among thyroidectomies. To our best knowledge, this study provided evidence of association using a large cohort population sample with different surgical procedures for thyroid disorders. Patients' proportion who developed postoperative hypothyroidism is substantial and varying from 10% to 45% depending on the type of surgical procedure.

The findings were startling in that 23.46% were bilateral total 23.76% one-side total and another-side-subtotal surgery associated with greater risk to postoperative hypothyroidism as compared with unilateral-subtotal. However, no significant association was observed in patients with a unilateral total surgical procedure for hypothyroidism. These findings show that the more extensive and substantial surgical procedure would have greater risk to develop postoperative hypothyroidism. Nevertheless, all patients encountered postoperative hypothyroidism temporarily which subsided during the study period which indicates a transient hypothyroidism. Our findings are consistent with [@B29], [@B21] and [@B7] that hypothyroidism was a temporary condition and did not reoccur after more than one year post thyroidectomy. However, some studies reported that most of the subtotal thyroidectomy patients showed hypothyroidism after surgery as the long-term outcome ([@B38]). [@B13] reported that patients undergoing subtotal thyroidectomy are not protected against early or late postoperative hypothyroidism.

In this study, 1048 patients with non-toxic multinodular goiter underwent bilateral-subtotal surgery, 867 patients with unspecified nontoxic nodular goiter had unilateral total surgery and 867 patients underwent thyroidectomy among other thyroid disorders (see [**Table 3**](#T3){ref-type="table"}). It is revealed that among surgeries, bilateral-subtotal surgical procedures were the most common we observed, with 32.56% patients having non-toxic multinodular goiter. However, most of the patients with thyroid cancer received total thyroidectomy and radioiodine ablation therapy. The reason for these procedures is to prevent a thyroid disorder from becoming hypothyroidism. Usually, multinodular goiter is less likely to develop into thyroid cancer but unilateral nodular goiter has a relatively higher thyroid cancer incidence as compared to multinodular. This might be one of the important reasons that these patients receive unilateral surgery more frequently.

[@B16] reported that the incidence of hypothyroidism following thyroid lobectomy is low, and a significant proportion of individuals who become biochemically hypothyroid will reveal only a transient elevation in their TSH levels. We observed that radical thyroidectomy with unilateral neck lymph node dissection had increased incidence of patients with thyroid cancer (88.14%) compared to bilateral total surgical procedure (45.06%). All types of thyroid cancer such as papillary, follicular, medullary, or anaplastic could be removed by using complete thyroid resection surgery. In some cases, if the tissues could not be fully removed, then radioactive iodine therapy is often used to destroy the tissues.

In this current study, we also investigated cumulative incidences of post-operative hypothyroidism in patients undergoing surgery for any thyroid disorder during a time period of weeks, months and years. For a time period of 1--4 weeks, 340 patients developed postoperative hypothyroidism during the second week following thyroid related surgery which subsided to normal within 3 to 8 weeks. For a period of 2--12 months, 480 patients developed postoperative hypothyroidism and which subsided in 2--3 months after thyroid surgery. Similar trends were observed for periods of 1--12 years where almost 1000 patients underwent surgery and developed postoperative hypothyroidism only shortly after surgery, which subsided within the 2--12 years of our study period. Interestingly, we observed almost the same trends for different periods (weeks, months and years) which showed a transient hypothyroidism after surgery for temporarily which subsided afterwards. Our findings are consistent with previous studies in that hypothyroidism is associated with total thyroidectomy and occurred frequently, however, it could be managed as compared to hypoparathyroidism ([@B22]). Verloop et al.'s meta-analysis ([@B48]) showed that approximately one in five patients will develop hypothyroidism after hemithyroidectomy, with clinical hypothyroidism in one of 25 patients undergoing surgery. [@B43] observed a 70% incidence of hypothyroidism associated with hemithyroidectomy.

[@B41] reported that the surgical techniques and extent of resection had a greater influence on permanent postoperative hypoparathyroidism than thyroid pathologic condition. [@B23] found that 16.7% transient hypoparathyroidism is associated with tumor enlargement and the appearance of novel lymph node metastases surgeries. [@B24] and [@B37] reported that 10% of the patients encountered an unexpected permanent postoperative hypothyroidism, despite choosing a surgical procedure to avoid drug usage for longer periods. While medical therapy with an anti-thyroid drug is commonly adopted in European nations and Japan as the first-choice method of therapy, the disease still often occurs. Recent systematic review reported the clinical, behavioral and pharmacogenomic factors could be influence in response to levothyroxine therapy in patients with primary hypothyroidism ([@B6]).

Moreover, the literature on the opinions of thyroid surgeries experts is somewhat controversial. [@B35] and [@B34] reported that surgeons experience is associated with complication rates. We observed in thyroid cancer patients that half of them took conservative surgeries (unilateral-subtotal, bilateral-subtotal and unilateral-total) and more than half took aggressive surgery (bilateral-total, unilateral-total and unilateral-subtotal, and radical thyroidectomy) with unilateral neck lymph node. The surgical procedure often took place in consideration to the cancer cell type, and stage and size of nodules. After thyroidectomy, the transient hypothyroidism often occurring in patients is associated with blood loss during surgery. This usually subsides once the tissue regeneration and blood perfusion occurs, which leads to the thyroid gland functions returning to normal.

The findings of this study should be interpreted by acknowledging that we did not have access to the type of cancer cells, tumor stage and nodules size information, as we used Taiwan NHI database which only contains claims data. Some limitations may be inevitable in this retrospective NHIRD study. However, our study was still valuable because it is a population-based nationwide long-term study and the NHIRD records included a large sample size (1 million random individuals) with the general representation (covered more than 99% Taiwan citizens). Moreover, the National Health Insurance is a nationwide legislative policy based on National Health Insurance Act and is governed by National Health Insurance Administration, Ministry of Health and Welfare, Republic of China (Taiwan). Insurance claims are scrutinized by official medical specialists and monitored by peer reviewers according to standard diagnostic criteria. Although we used multiple methods during the inclusion process to identify the diagnosis and to minimize misclassification, a few atypical cases may still present difficulties in classification and this issue we further try to deal by ensuring the patients long term follow-up.

Conclusion {#s5}
==========

The most significant findings to emerge from this study is that thyroidectomy was associated with transient postoperative hypothyroidism in thyroid disorder patients. The research has also shown that the risk was associated with different surgical procedures for thyroid disorders as well. Postoperative hypothyroidism usually occurs only temporarily and subsides afterwards.
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